A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/44 (2006.01) A61K 31/55 (2006.01) A61K 45/06 (2006.01) A61P 9/00 (2006.01) A61P 9/02 (2006.01) A61P 9/04 (2006.01) A61P 9/10 (2006.01) A61P 9/12 (2006.01) A61P 11/00 (2006.01) A61P 27/00 (2006.01) A61P 43/00 (2006.01)
Patent
CA 2432282
The present invention especially relates to the use of a combination comprising (1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceuticall acceptable salts thereof, and (2) amlodipine or pharmaceutically acceptable salt thereof, for the manufacture a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache; wherein (i) the amount of amlodipine or a pharmaceutically acceptable salt thereof corresponds to 6 about mg to 40 about mg of the free base and (ii) the amount of the ACE inhibitor or a pharmaceutically thereof corresponds to 20 about mg to 160 about mg of benazepril hydrochloride.
L'invention concerne en particulier l'utilisation d'une combinaison comprenant (1) un ACEI (inhibiteur d'enzyme convertissant l'angiotensine) choisi dans le groupe form~ de b~naz~pril, b~naz~prilate et de sels de ceux-ci pharmaceutiquement acceptables, et (2) une amlodipine ou un sel de celle-ci pharmaceutiquement acceptable, destin~e ~ la fabrication d'un m~dicament pour traiter, pr~venir ou retarder la progression d'une affection faisant partie du groupe hypertension, insuffisance cardiaque globale, angine, infarctus du myocarde, art~rioscl~rose, n~phropathie diab~tique, cardiomyopathie diab~tique, insuffisance r~nale, maladie p~ri-vasculaire, hypertrophie ventriculaire gauche, dysfonctionnement cognitif, maladie c~r~brovasculaire associ~e ~ la pression sanguine, accident c~r~brovasculaire, maladie pulmonaire ou hypertension pulmonaire et c~phal~e. (i) La dose d'amlodipine ou d'un sel de celle-ci pharmaceutiquement acceptable se situe entre environ 6 mg et environ 40 mg de la base libre et (ii) la dose de l'inhibiteur ACE ou d'un sel de celui-ci pharmaceutiquement acceptable se situe entre environ 20 mg et environ 160 mg de chlorhydrate de b~naz~pril.
Comfort Ann Reese
Daley William Lionel
Fleres Santo Joseph
Royce Alan Edward
Webb Randy Lee
Fetherstonhaugh & Co.
Novartis Ag
LandOfFree
Therapeutic combination of amlodipine and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic combination of amlodipine and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic combination of amlodipine and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1410053